How are ACAD long call max profit and max loss calculated?

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ACAD long call priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 43.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$187.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ACAD long call?

The breakeven for the ACAD long call priced on this page is roughly $29.88 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ACAD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 12.44%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ACAD implied volatility affect this long call?

ACAD ATM IV is at 43.40% with IV rank near 40.00%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

ACAD Long Call Strategy

ACAD (ACADIA Pharmaceuticals Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain.

ACAD (ACADIA Pharmaceuticals Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $5.04B, a trailing P/E of 13.28, a beta of 0.85 versus the broader market, a 52-week range of 19.69-29.84, average daily share volume of 1.7M, a public-listing history dating back to 2004, approximately 797 full-time employees. These structural characteristics shape how ACAD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.85 places ACAD roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a long call on ACAD?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

ACAD snapshot

As of August 14, 2026, spot at $28.43, ATM IV 43.40%, IV rank 40.00%, expected move 12.44%. The long call on ACAD below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this long call structure on ACAD specifically: ACAD IV at 43.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 12.44% (roughly $3.54 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ACAD expiries trade a higher absolute premium for lower per-day decay. Position sizing on ACAD should anchor to the underlying notional of $28.43 per share and to the trader's directional view on ACAD stock.

ACAD long call setup

The ACAD long call below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ACAD at $28.43 on that close, the first option leg uses a $28.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ACAD chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ACAD shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$28.00	$1.88

ACAD long call risk and reward

Net Premium / Debit: -$187.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$187.50
Breakeven(s): $29.88
Risk / Reward Ratio: Unbounded

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

ACAD long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on ACAD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	-$187.50
$6.29	-77.9%	-$187.50
$12.58	-55.8%	-$187.50
$18.86	-33.6%	-$187.50
$25.15	-11.5%	-$187.50
$31.43	+10.6%	+$155.96
$37.72	+32.7%	+$784.45
$44.00	+54.8%	+$1,412.95
$50.29	+76.9%	+$2,041.44
$56.57	+99.0%	+$2,669.93

When traders use long call on ACAD

Long calls on ACAD express a bullish thesis with defined risk; traders use them ahead of ACAD catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

ACAD thesis for this long call

The market-implied 1-standard-deviation range for ACAD extends from approximately $24.89 on the downside to $31.97 on the upside. A ACAD long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ACAD IV rank near 40.00% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on ACAD should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ACAD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ACAD-specific events.

ACAD long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ACAD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ACAD alongside the broader basket even when ACAD-specific fundamentals are unchanged. Long-premium structures like a long call on ACAD are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ACAD chain quotes before placing a trade.

Frequently asked questions

What is a long call on ACAD?: A long call on ACAD is the long call strategy applied to ACAD (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ACAD stock at $28.43 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed ACAD chain strike and the premiums come straight from that session's bid/ask midpoint.
How are ACAD long call max profit and max loss calculated?: Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ACAD long call priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 43.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$187.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ACAD long call?: The breakeven for the ACAD long call priced on this page is roughly $29.88 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ACAD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 12.44%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on ACAD?: Long calls on ACAD express a bullish thesis with defined risk; traders use them ahead of ACAD catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current ACAD implied volatility affect this long call?: ACAD ATM IV is at 43.40% with IV rank near 40.00%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.